文献速递胸部肿瘤

晚期EGFR突变肺癌治疗耐药的管理:个体化、精简与协作

Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
PubMed 文献 · J Clin Oncol · 2024-02-27

本文为《临床肿瘤学杂志》肿瘤学大查房系列文章,通过病例展示引出晚期EGFR突变非小细胞肺癌获得性耐药及中枢神经系统进展后的管理挑战,结合文献回顾总结作者建议的管理策略,强调根据临床、分子及个体因素进行个体化治疗分层与患者协作。

要点

  • 晚期EGFR突变非小细胞肺癌一线EGFR酪氨酸激酶抑制剂初始可耐受且疗效持久。
  • 获得性耐药和中枢神经系统进展在病程中不可避免,是照护连续体中的挑战性转折。
  • 后续治疗通常需联合用药,在疗效、毒性和生活质量方面存在细微差异,需个体化分层并与患者协作。

核心结论

  • 晚期EGFR突变非小细胞肺癌患者获得性耐药和中枢神经系统进展不可避免,后续治疗需进一步个体化并与患者协作,以识别关键临床、分子和个体因素来指导最优照护。

研究设计与样本

  • 肿瘤学大查房系列文章,以病例展示开始,随后描述诊断和管理挑战、回顾相关文献并总结作者建议的管理方法。

主要发现

  • 晚期EGFR突变非小细胞肺癌患者一线EGFR导向酪氨酸激酶抑制剂初始可耐受且效果持久。
  • 获得性治疗耐药和中枢神经系统癌症进展在疾病过程中不可避免。
  • 后续治疗通常需要药物联合,相对于既往治疗体验、毒性特征和生活质量,临床结局存在细微差异。

临床怎么用

  • 治疗分层和调节需要进一步个体化并与患者协作,以识别关键临床、分子和个体特异性因素来最佳指导 optimal 照护。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer represent a distinct subgroup of individuals who can experience initially tolerable and durable effects with first-line EGFR-directed tyrosine kinase inhibitors. Unfortunately, acquired treatment resistance and cancer progression within the CNS are inevitable during the disease course and present a challenging transition in the care continuum. Next-line therapies generally require combinations of drugs and afford nuanced differences in clinical outcomes relative to the treatment experience, toxicity profile, and quality of life. Therapeutic stratification and modulation thus require further personalization and partnership with patients to identify key clinical, molecular, and human-specific factors to best guide optimal care.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Piper Vallillo AJ, Viray H, Feldman J, et al. Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership. J Clin Oncol. 2024. PMID: 38412397. doi:10.1200/JCO.23.02417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。